Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Eisai
Eisai
X
LinkedIn
Trending Articles
AbbVie and Gedeon Richter join forces to advance neuropsychiatric target R&D
The companies will aim to discover and progress targets for neuropsychiatric disorders
Containment in a high potent manufacturing facility
Throughout the pharmaceutical industry, there is a lack of consistency regarding the assignment of Occupational Exposure Limits (OELs) to specific bands
Rousselot
Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Causes and solutions for dark spots in tablet manufacturing
Natoli Engineering examines the causes and solutions for dark spots that can halt production
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
Alzheimer's drug lecanemab deemed unsuitable for the UK NHS by health regulator
The drug will not be available on the NHS owing to significant and potentially life-threatening side effects, as well as the cost of the medicine and its limited efficacy
Regulatory
FDA grants landmark approval for Alzheimer’s treatment
LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
Regulatory
AbbVie and Eisai launch online Humira support tool service
The free-of-charge service assists patients on Humira therapy by delivering support tools to their home or other requested location
Finance
Eisai and Fuji Yakuhin sign ASEAN distribution agreement for gout therapy
Hyperuricemia is known to be associated with various diseases in the urinary system, endocrine system, metabolic system, cardio-cerebrovascular system etc., including gout
Research & Development
Eisai and Biogen announce Phase IV Alzheimer's study design
The companies will be evaluating the long-term effectiveness and safety data of Biogen's Alzheimer's therapy, Aduhelm
Regulatory
Eisai and Merck combination cancer therapy approved by FDA
The approval for this population is based on results from a Phase III Study 309/KEYNOTE-775 trial
Research & Development
Eisai makes major investments in drug creation
Platform will be established to combine Eisaid know-how with external big data and genomic data for drug innovation in neurology and oncology
Subscribe now